Compare FOXX & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOXX | RNXT |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | 25 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 37.0M |
| IPO Year | N/A | 2021 |
| Metric | FOXX | RNXT |
|---|---|---|
| Price | $4.62 | $0.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | ★ 4.4M | 318.2K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $1.71 | $0.70 |
| 52 Week High | $8.70 | $1.45 |
| Indicator | FOXX | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 46.08 |
| Support Level | $4.03 | $0.79 |
| Resistance Level | $5.15 | $1.07 |
| Average True Range (ATR) | 0.89 | 0.07 |
| MACD | 0.24 | 0.00 |
| Stochastic Oscillator | 41.62 | 37.82 |
Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.